In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens
- 1 April 2002
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 8 (4) , 410-414
- https://doi.org/10.1038/nm0402-410
Abstract
Minor histocompatibility antigens (mHags) are immunogenic peptides from polymorphic cellular proteins that induce strong T-cell responses after human leukocyte antigen (HLA)-matched, mHag-mismatched stem-cell transplantation1,2. mHags with broad or limited tissue expression are target antigens for graft-versus-host (GvH) and graft-versus-leukemia (GvL) reactivities1. Separation of these activities is crucial for adoptive immunotherapy of leukemia without GvH disease. Therefore, using a skin-explant assay we investigated the in situ activities of cytotoxic T lymphocytes (CTLs) specific for the ubiquitously expressed mHag H-Y and for the hematopoietic-restricted mHags HA-1 and HA-2. H-Y-specific CTLs, visualized by tetrameric HLA–mHag peptide complexes3, infiltrated male skin sections within 24 hours, induced severe GvH reactions of grade III–IV and produced high levels of IFN-γ. In contrast, CTLs specific for the hematopoietic system–specific mHags HA-1 and HA-2 induced no or low GvH reactions above background and produced little or no interferon-γ, unless the skin sections were preincubated with HA-1/HA-2 synthetic peptides. These results provide the first in situ dissection of GvH effects by mHag-specific CTLs and show that ubiquitously expressed mHags are the prime targets of GvH disease.Keywords
This publication has 20 references indexed in Scilit:
- Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host diseaseNature Medicine, 2001
- In situ detection of virus- and tumor-specific T-cell immunityNature Medicine, 2000
- Prevention of Graft Versus Host Disease by Inactivation of Host Antigen-Presenting CellsScience, 1999
- Tetrameric HLA class I–minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host diseaseNature Medicine, 1999
- Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxisBone Marrow Transplantation, 1999
- PREDICTING GRAFT-VERSUS-HOST DISEASE IN HLA-IDENTICAL BONE MARROW TRANSPLANTSTransplantation, 1998
- Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapyImmunological Reviews, 1997
- Mismatches of Minor Histocompatibility Antigens between HLA-Identical Donors and Recipients and the Development of Graft-Versus-Host Disease after Bone Marrow TransplantationNew England Journal of Medicine, 1996
- Immunogenetics of human minor histocompatibility antigens: their polymorphism and immunodominanceImmunogenetics, 1992
- An in Vitro Predictive Test for Graft versus Host Disease in Patients with Genotypic HLA-Identical Bone Marrow TransplantsNew England Journal of Medicine, 1985